OverC Multi-Cancer Detection
Blood-based cfDNA methylation multi-cancer early detection test with six-cancer current product scope; jurisdiction-specific regulatory status.
- Developer
- Burning Rock Dx
- Intended use
- Multi Cancer Screening
- Cancer scope
- Not reported
- Specimen
- Peripheral whole blood
- Molecular modality
- DNA methylation
- Current version
- Current OverC product snapshot (2026)
- Evidence context
- 1 structured studies · 0 indexed performance results · 2 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.